Supernus Pharmaceuticals, Inc. (FRA:S49)

Market Cap	2.48B +18.3%
Revenue (ttm)	580.88M +4.5%
Net Income	-16.29M
EPS	-0.29
Shares Out	n/a
PE Ratio	n/a
Forward PE	27.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	15
Open	43.60
Previous Close	42.40
Day's Range	43.60 - 43.60
52-Week Range	26.20 - 49.00
Beta	n/a
RSI	58.59
Earnings Date	Feb 24, 2026

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN...

• Industry: Pharmaceutical Preparations
• Founded: 2005
• Employees: 674
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: S49

Financial Performance

In 2024, Supernus Pharmaceuticals's revenue was $661.82 million, an increase of 8.94% compared to the previous year's $607.52 million. Earnings were $73.87 million, an increase of 5512.84%.

Financial numbers in USD